Last reviewed · How we verify
NCT05156905
Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer
Phase 1 trial testing Cirmtuzumab in Metastatic Castration-resistant Prostate Cancer in 6 participants. Terminated before completion.
1 October 2024
Quick facts
| Lead sponsor | University of California, San Diego |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 16 June 2022 |
| Primary completion | 1 October 2024 |
| Estimated completion | 1 October 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Cirmtuzumab — full drug profile →
Conditions studied
- Metastatic Castration-resistant Prostate Cancer — all drugs for Metastatic Castration-resistant Prostate Cancer →
Sponsor
University of California, San Diego
Who can join
18 and older, male only, with Metastatic Castration-resistant Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to examine the safety and efficacy of cirmtuzumab in combination with standard of care docetaxel in patients with metastatic castration resistant prostate cancer. Docetaxel is a taxane chemotherapy which has been shown to prolong survival in men with castration resistant prostate cancer. Cirmtuzumab is a monoclonal antibody that targets the receptor called ROR1 of the non-canonical Wnt pathway and is suspected to contribute to prostate cancer growth and progression.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy.
Song P, Gao Z, Bao Y, Chen L, et al · · 2024 · cited 208× · PMID 38886806 · DOI 10.1186/s13045-024-01563-4 -
Signaling pathways in the regulation of cancer stem cells and associated targeted therapy.
Manni W, Min W. · · 2022 · cited 52× · PMID 36226253 · DOI 10.1002/mco2.176 -
Wnt signaling in cancer: from biomarkers to targeted therapies and clinical translation.
Tufail M, Jiang CH, Li N. · · 2025 · cited 36× · PMID 40170063 · DOI 10.1186/s12943-025-02306-w -
Exploring the Wnt Pathway as a Therapeutic Target for Prostate Cancer.
Koushyar S, Meniel VS, Phesse TJ, Pearson HB. · · 2022 · cited 33× · PMID 35204808 · DOI 10.3390/biom12020309 -
Profiling and targeting cancer stem cell signaling pathways for cancer therapeutics.
Borlongan MC, Wang H. · · 2023 · cited 30× · PMID 37305676 · DOI 10.3389/fcell.2023.1125174 -
Targeting ligand-dependent wnt pathway dysregulation in gastrointestinal cancers through porcupine inhibition.
Flanagan DJ, Woodcock SA, Phillips C, Eagle C, et al · · 2022 · cited 26× · PMID 35358569 · DOI 10.1016/j.pharmthera.2022.108179 -
Crosstalk between Wnt/β-catenin signaling pathway and DNA damage response in cancer: a new direction for overcoming therapy resistance.
Zhang X, Yu X. · · 2023 · cited 19× · PMID 37601042 · DOI 10.3389/fphar.2023.1230822 -
High-purity CTC RNA sequencing identifies prostate cancer lineage phenotypes prognostic for clinical outcomes.
Sharifi MN, Sperger JM, Taylor AK, Tippins KE, et al · · 2025 · cited 14× · PMID 39912912 · DOI 10.1158/2159-8290.cd-24-1509
Verify or expand the search:
- PubMed search for NCT05156905
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cirmtuzumab
Trials testing the same drug.
- NCT04501939 — Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax · Phase 2 · active not recruiting
Other recruiting trials for Metastatic Castration-resistant Prostate Cancer
Currently open trials in the same condition.
- NCT07142551 — Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response · Phase 2 · recruiting
- NCT07288359 — Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and · Phase 1, PHASE2 · recruiting
- NCT07244341 — A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer ( · Phase 1 · recruiting
- NCT07213674 — A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic · Phase 3 · recruiting
- NCT07189403 — A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resist · Phase 1 · recruiting
Other University of California, San Diego trials
Trials by the same sponsor.
- NCT07342543 — Guided Physical Activity Counseling for Hypertension in Primary Care · NA · not yet recruiting
- NCT06505317 — Artificial Intelligence for Early Detection of Peripheral Artery Disease · NA · not yet recruiting
- NCT07211802 — CKM For Safe Use of SGLT2i in Type 1 Diabetes · Phase 3 · not yet recruiting
- NCT07524751 — Culturally Adapted Pain Management for Indigenous Peoples · NA · not yet recruiting
- NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05156905 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, San Diego
- Last refreshed: 9 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05156905.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing